RxDoctor Payments Data

Aisha Shareef, MD

Neurology · Crown Point, INNPI 1669632964

Payments from drug & device makers

$24,897in general payments, 2019–2025

Across 1,175 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Biogen$2K
  • AbbVie$2K
  • MDD US Operations, LLC$1K
  • UCB, Inc.$991
  • Sanofi$947
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$400%
  • Food & beverage$22,09689%
  • Education$280%
  • Gifts$2,73311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis60$3,609
Biogen86$1,758
AbbVie(2 entities)108$1,597
MDD US Operations, LLC74$1,278
UCB, Inc.64$991
Sanofi37$947
Lilly USA, LLC42$811
Teva Pharmaceuticals USA, Inc.44$774
EMD Serono, Inc.34$766
Lundbeck LLC36$650
Neurelis, Inc.24$616
Pfizer38$577
AstraZeneca(2 entities)25$560
Sunovion Pharmaceuticals Inc.36$559
SK Life Science, Inc.38$551
Argenx US, Inc.24$515
Amneal Pharmaceuticals LLC23$455
Neurocrine Biosciences, Inc.20$449
Bristol Myers Squibb18$433
Genentech USA, Inc.19$424
Amgen20$424
Eisai Inc.20$395
Upsher-smith Laboratories LLC19$382
Banner Life Sciences, LLC15$375
Livanova USA, Inc.18$320
CSL Behring10$315
Acadia Pharmaceuticals Inc16$273
Corium, LLC16$268
Catalyst Pharmaceuticals, Inc.16$266
Acorda Therapeutics, Inc12$244
Takeda Pharmaceuticals U.S.A., Inc.13$237
Jazz Pharmaceuticals Inc.13$233
Biohaven Pharmaceutical Holding Company Ltd.13$224
Johnson & Johnson(2 entities)9$203
Vanda Pharmaceuticals Inc.12$200
Biohaven Pharmaceuticals, Inc.12$161
Kyowa Kirin, Inc.6$144
Avanir Pharmaceuticals, Inc.3$131
E.r. Squibb & Sons, L.L.C.1$125
Tanabe Pharma America, Inc.6$118
Supernus Pharmaceuticals, Inc.7$112
Chiesi USA, Inc.6$107
ANI Pharmaceuticals, Inc.4$101
Otsuka America Pharmaceutical, Inc.5$94
EKOS Corporation1$93
Impel Pharmaceuticals LLC5$93
TG Therapeutics, Inc.5$91
Cycle Pharmaceuticals Inc4$91
Adamas Pharmaceuticals, Inc.4$79
Abbott3$70
Medtronic4$66
Sumitomo Pharma America, Inc.4$64
Greenwich Biosciences, Inc.2$62
Impel Pharmaceuticals Inc.3$54
Octapharma USA, Inc.2$49
Bausch Health US, LLC2$42
Scilex Pharmaceuticals Inc.2$40
Ipsen Biopharmaceuticals, Inc2$39
Ceribell, Inc.2$36
Stryker2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,897 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$240,054
Medicare patients
568
Services billed
2,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5026$224,688
NuplazidPimavanserin Tartrate25$152,778
VumerityDiroximel Fumarate12$120,114
Nurtec OdtRimegepant Sulfate70$116,364
GocovriAmantadine Hcl28$99,743
BriviactBrivaracetam18$42,265
Emgality PenGalcanezumab-Gnlm33$40,072
FycompaPerampanel20$39,115
Teriflunomide30$36,395
QuliptaAtogepant32$35,601
Aimovig AutoinjectorErenumab-Aooe26$27,917
UbrelvyUbrogepant26$27,006
BotoxOnabotulinumtoxina22$26,594
Ajovy AutoinjectorFremanezumab-Vfrm12$26,060
XcopriCenobamate19$22,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$577$341,05296 claims
Acadia Pharmaceuticals IncNuplazid$273$152,77825 claims
BiogenVumerity$1,758$120,11412 claims
MDD US Operations, LLCGocovri$1,278$99,74328 claims
AbbVieQulipta, Ubrelvy, Botox$1,597$89,20180 claims
UCB, Inc.Briviact$991$42,26518 claims
Eisai Inc.Fycompa$395$39,11520 claims
SK Life Science, Inc.Xcopri$551$22,34919 claims
AstraZenecaBrilinta$560$4,88211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →